Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)

Inclusion Criteria

• •Pathological diagnosis of NSCLC with confirmed activation of driver gene mutation (EGFR mutant: exon 19 deletion or exon 21 L858R mutation; ALK-rearrangement) by amplification refractory mutation system (ARMS);
• •stage IIIB-IV according to the eighth edition of the American Joint Committee on Cancer staging system confirmed by pathological diagnosis and positron emission tomography-computed tomography (PET-CT) and biopsy
• •Written informed consent provided；
• •Age 18-70 when signing the consent form, both male and female;
• •The ECOG score is 0 or 1;
• •Adequate hematological function, liver function and renal function;
• •Female participants should not be pregnant or breast-feeding.